The Carnot network for Advanced Therapy Medicinal Products
The Carnot Institutes are structured to harness their complementarity and unlock the synergies needed to come up with R&D solutions for tackling the key challenges facing businesses in different industries.
The Carnot network for Advanced Therapy Medicinal Products (ATMPs)
MTIs are gene-, tissue- or cell-based drugs, some of which combine one or more medical devices, offering innovative treatment options.
The Carnot network for Advanced Therapy Medicinal Products (ATMPs) offers industry agile access to unique advice and solutions to accelerate the R&D of biotherapy innovations.
The Carnot involved cover the full range of biomedical expertise and mastery of the processes and technologies needed to develop cutting-edge biomedicines, biomaterials and devices in various therapeutic fields. We support our partners across the entire R&D value chain: formulation and synthesis, new therapeutic targets, preclinical validation, imaging, biomarkers, clinical validation, real-life monitoring, bioproduction, biotesting.
Carnot involved : AP HP, CALYM, CEA LETI, Chimie Balard Cirimat, Curie Cancer, I2C, Brain Institute, Imagine, OPALE et Voir & Entendre
